Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial - Van Oers, M H; Klasa, R; Marcus, R E (Blood, 2006)
et al.